Compounds > bis-neodecanoato-1,2-diaminocyclohexaneplatinum(ii)
Page last updated: 2024-12-07

bis-neodecanoato-1,2-diaminocyclohexaneplatinum(ii)

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID115360
MeSH IDM0153572

Synonyms (2)

Synonym
bis-neodecanoato-1,2-diaminocyclohexaneplatinum(ii)
(2-azanidylcyclohexyl)azanide;7,7-dimethyloctanoate;platinum(4+)

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The subacute mouse LD50 of L-Pt preparations tested ranged from 60 to 104 mg/kg."( Toxicity and efficacy studies on a series of lipid-soluble dineodecanoato(trans-R,R- and trans-S,S-1,2-diaminocyclohexane) platinum (II) complexes entrapped in liposomes.
al-Baker, S; Khokhar, AR; Perez-Soler, R, 1992)		0.28
" At the LD50 dose (i."( Preclinical toxicity and pharmacology of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II).
Khokhar, AR; Lautersztain, J; Perez-Soler, R; Stephens, LC; Wright, K, 1989)		0.28
" LD50 in mice of free NDDP and L-NDDP were similar (79."( Increased cytotoxicity and reversal of resistance to cis-diamminedichloro-platinum(II) with entrapment of cis-Bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum (II) in multilamellar lipid vesicles.
Drewinko, B; Khokhar, AR; Lauterzstain, J; Perez-Soler, R; Yang, LY, 1988)		0.27

Dosage Studied

ExcerptRelevanceReference
" Six of the 10 cats were given doses of L-NDDP at the maximum tolerated dosage (100 mg/m2) or a lower dosage (75 mg of L-NDDP/m2) at 21-day intervals, for a total of 4 treatments."( Evaluation of toxicosis of liposome-encapsulated cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II) in clinically normal cats.
Calderwood-Mays, M; Fox, LE; Khokhar, AR; Kubilis, P; MacEwen, EG; Perez-Soler, R; Toshach, K, 1999)		0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (24)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (20.83)18.7374
1990's14 (58.33)18.2507
2000's5 (20.83)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.13

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.13 (24.57)
Research Supply Index3.47 (2.92)
Research Growth Index4.60 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.13)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (14.81%)5.53%
Reviews2 (7.41%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other21 (77.78%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase II Study of Aroplatin in Subjects With Recurrent, Unresectable and Metastatic Colorectal Cancer Refractory to 5-Fluorouracil (5-FU)/Leucovorin or Capecitabine, and Irinotecan [NCT00043199]Phase 240 participants InterventionalActive, not recruiting
A Phase I/II Study of Aroplatin and Gemcitabine In Subjects With Unresectable, Locally Advanced And/Or Metastatic Pancreatic Cancer [NCT00081549]Phase 1/Phase 2111 participants InterventionalActive, not recruiting
A Phase I/II Study of Aroplatin™ in Patients With Advanced Solid Malignancies [NCT00057395]Phase 1/Phase 240 participants InterventionalActive, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
quinazolines
Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.		3.0810azaarene;
mancude organic heterobicyclic parent;
ortho-fused heteroarene;
quinazolines
platinum
Platinum: A heavy, soft, whitish metal, resembling tin, with atomic number 78, atomic weight 195.084, symbol Pt. It is used in manufacturing equipment for laboratory and industrial use. It occurs as a black powder (platinum black) and as a spongy substance (spongy platinum) and may have been known in Pliny's time as alutiae.		3.0750elemental platinum;
nickel group element atom;
platinum group metal atom
technetium
Technetium: The first artificially produced element and a radioactive fission product of URANIUM. Technetium has the atomic symbol Tc, and atomic number 43. All technetium isotopes are radioactive. Technetium 99m (m=metastable) which is the decay product of Molybdenum 99, has a half-life of about 6 hours and is used diagnostically as a radioactive imaging agent. Technetium 99 which is a decay product of technetium 99m, has a half-life of 210,000 years.		3.411manganese group element atom
dw a 2114r
[no description available]		3.0810platinum coordination entity;
pyrrolidines		antineoplastic agent
nsc 251635
[no description available]		3.0810
dimyristoylphosphatidylglycerol
[no description available]		2.6730
carboplatin
[no description available]		3.0810
dimyristoylphosphatidylcholine
1,2-di-O-myristoyl-sn-glycero-3-phosphocholine : A 1,2-diacyl-sn-glycero-3-phosphocholine where the two phosphatidyl acyl groups are specified as tetradecanoyl (myristoyl).. dimyristoyl phosphatidylcholine : A phosphatidylcholine where the phosphatidyl acyl groups are specified as tetradecanoyl (myristoyl).		2.9401,2-diacyl-sn-glycero-3-phosphocholine;
phosphatidylcholine 28:0;
tetradecanoate ester		antigen;
mouse metabolite
enloplatin
enloplatin: structure given in first source		3.0810
g(m1) ganglioside
G(M1) Ganglioside: A specific monosialoganglioside that accumulates abnormally within the nervous system due to a deficiency of GM1-b-galactosidase, resulting in GM1 gangliosidosis.. ganglioside GM1 : A sialotetraosylceramide consisting of a branched pentasaccharide made up from one sialyl residue, two galactose residues, one N-acetylgalactosamine residue and a glucose residue at the reducing end attached to N-stearoylsphingosine via a beta-linkage.		1.9910alpha-N-acetylneuraminosyl-(2->3)-[beta-D-galactosyl-(1->3)-N-acetyl-beta-D-galactosaminyl-(1->4)]-beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1')-N-acylsphingosine;
sialotetraosylceramide
phosphatidylcholines
Phosphatidylcholines: Derivatives of PHOSPHATIDIC ACIDS in which the phosphoric acid is bound in ester linkage to a CHOLINE moiety.		1.99101,2-diacyl-sn-glycero-3-phosphocholine
nk 121
NK 121: structure given in first source		3.0810
nedaplatin
nedaplatin: structure given in first source		3.0810
ConditionIndicatedRelationship StrengthStudiesTrials
Adenocarcinoma, Basal Cell
[description not available]		04.3522
Cancer of Ovary
[description not available]		04.8542
Peritoneal Carcinomatosis
[description not available]		03.411
Colorectal Cancer
[description not available]		04.3722
Signet Ring Cell Carcinoma
[description not available]		03.411
Endolymphatic Stromal Myosis
[description not available]		03.411
Adenocarcinoma
A malignant epithelial tumor with a glandular organization.		04.3522
Ascites
Accumulation or retention of free fluid within the peritoneal cavity.		03.411
Mesothelioma
A tumor derived from mesothelial tissue (peritoneum, pleura, pericardium). It appears as broad sheets of cells, with some regions containing spindle-shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos. (Dorland, 27th ed)		0533
Ovarian Neoplasms
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.		04.8542
Peritoneal Neoplasms
Tumors or cancer of the PERITONEUM.		03.411
Colorectal Neoplasms
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.		04.3722
Carcinoma, Signet Ring Cell
A poorly differentiated adenocarcinoma in which the nucleus is pressed to one side by a cytoplasmic droplet of mucus. It usually arises in the gastrointestinal system.		03.411
Neoplasms, Pleural
[description not available]		04.3622
Lassitude
[description not available]		03.4111
Blood Diseases
[description not available]		03.7821
Bilirubinemia
[description not available]		03.4111
Peripheral Nerve Diseases
[description not available]		03.4111
Emesis
[description not available]		03.4111
Fatigue
The state of weariness following a period of exertion, mental or physical, characterized by a decreased capacity for work and reduced efficiency to respond to stimuli.		03.4111
Hematologic Diseases
Disorders of the blood and blood forming tissues.		03.7821
Nausea
An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.		03.4111
Peripheral Nervous System Diseases
Diseases of the peripheral nerves external to the brain and spinal cord, which includes diseases of the nerve roots, ganglia, plexi, autonomic nerves, sensory nerves, and motor nerves.		03.4111
Vomiting
The forcible expulsion of the contents of the STOMACH through the MOUTH.		03.4111
Carcinoma, Anaplastic
[description not available]		01.9810
Cancer of Colon
[description not available]		01.9810
Carcinoma
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.		01.9810
Colonic Neoplasms
Tumors or cancer of the COLON.		01.9810
Fibrosarcoma
A sarcoma derived from deep fibrous tissue, characterized by bundles of immature proliferating fibroblasts with variable collagen formation, which tends to invade locally and metastasize by the bloodstream. (Stedman, 25th ed)		01.9910
B16 Melanoma
[description not available]		02.3820
Leukemia L 1210
[description not available]		03.0750
Cancer of Lung
[description not available]		03.3811
Lung Neoplasms
Tumors or cancer of the LUNG.		03.3811
Pleural Effusion, Malignant
Presence of fluid in the PLEURAL CAVITY as a complication of malignant disease. Malignant pleural effusions often contain actual malignant cells.		03.3811
Carcinoma, Epidermoid
[description not available]		0210
Cancer of Mouth
[description not available]		0210
Cat Diseases
Diseases of the domestic cat (Felis catus or F. domesticus). This term does not include diseases of the so-called big cats such as CHEETAHS; LIONS; tigers, cougars, panthers, leopards, and other Felidae for which the heading CARNIVORA is used.		0210
Carcinoma, Squamous Cell
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)		0210
Mouth Neoplasms
Tumors or cancer of the MOUTH.		0210
Diffuse Large B-Cell Lymphoma
[description not available]		01.9810
Lymphoma, Large B-Cell, Diffuse
Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.		01.9810
Benign Neoplasms
[description not available]		04.0530
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		04.0530
Cancer of Liver
[description not available]		01.9710
Diffuse Mixed Small and Large Cell Lymphoma
[description not available]		01.9710
Liver Neoplasms
Tumors or cancer of the LIVER.		01.9710
Lymphoma, Non-Hodgkin
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.		01.9710
Experimental Hepatoma
[description not available]		02.3720